A Superior Approach to Profiting from Dividend Stock Investments
Written by Emily J. Thompson, Senior Investment Analyst
Source: MarketWatch
Alternative Dividend Strategy: There are more effective methods for collecting dividends than the traditional "Dogs of the Dow" strategy, which focuses on high-yield stocks.
Year-End Portfolio Rebalancing: Investors using the Dogs of the Dow strategy are preparing to adjust their portfolios to include the 10 highest-yielding stocks from the Dow Jones Industrial Average as the year concludes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 201.090
Low
183.00
Averages
202.38
High
220.00
Current: 201.090
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IHI Stock 52-Week Performance Analysis
- Price Range Analysis: IHI's stock has a 52-week low of $52.9047 and a high of $65.18, with the latest trade at $59.62, indicating significant price fluctuations that reflect market interest and investor sentiment.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping them assess price trends and potential buy or sell opportunities to optimize investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, reflecting dynamic market liquidity and investor behavior.
- Inflows and Outflows Monitoring: Weekly monitoring of ETFs for notable inflows (new units created) or outflows (old units destroyed) can impact the underlying stocks held within ETFs, influencing overall market performance and investor strategies.
Continue Reading
BD and Envetec Collaborate on Sustainable Medical Plastic Recycling
- Recyclability Study: BD and Envetec successfully completed a joint feasibility study indicating that high-quality polymers, such as polystyrene Petri dishes, can be recycled within the medical supply chain, thereby promoting sustainability in the healthcare sector.
- Technological Innovation: Envetec's GENERATIONS® technology transforms regulated medical waste into recyclable polymer flakes through a low-energy chemical disinfection process, marking a significant step towards a circular economy for medical plastics.
- Environmental Impact: This pilot project not only reduces reliance on virgin plastics but also provides sustainable solutions for the healthcare industry to avoid landfilling, facilitating the production of more environmentally friendly medical devices.
- Market Expansion Potential: BD plans to expand the pilot project to process more types of medical plastics using this technology, further promoting the circular use of high-value polymers and enhancing the environmental friendliness of medical devices.
Continue Reading